Phalanx Biotech Group diversifies its microarray offerings and aims to bolster acceptance of its genomic products and services
The Taiwan company has produced a flexible platform that can be used in numerous clinical applications
Country Business Reports interviews and articles by Discovery Reports www.discoveryreports.com
A Taiwan biotech company is diversifying its microarray offerings to deepen its imprint in Asia and to bolster the global acceptance of its genomic products and services.
Phalanx Biotech Group is one of only four high-throughput genomics solutions providers in the world, and it is the only one based outside the United States. It is shoring up its technology platform to unravel clinical and medical breakthroughs by applying analysis from its in-house research and development division.
Similar in make to computer microchips, microarrays have been used by scientists as a research tool to study gene changes and sequences that are associated with particular diseases.
Today, microarrays are used in clinical diagnostic tests, and are sometimes applied to determine which drugs are best for particular individuals.
One such application by Phalanx, the CytoOneArray, can detect clinically confirmed prenatal and postnatal diseases related to inherited disorders.
“After creating our OneArray products and installing world-class quality systems, the next goal is to make our offerings accessible,” says Sybil Yang, chairman and CEO.
“Based on more than 13 years of research, we have established a strong, scientific and well-validated footing to produce a flexible platform that can be used in numerous clinical applications.”
As a technology platform-enabling company, Phalanx can easily revise and optimise products using the latest information and technology. It is working on clinical and consumer genomics solutions, which include an instrumental application for the oncology field. To introduce its platform to Asean markets, Phalanx welcomes partnerships from mainland China and distributors from Singapore and Southeast Asia as it braces for a presumptive initial public offering in the midterm.
“People from the US, Europe and Asia have different genetic-related diseases, and as the only company of our kind in Asia, we can address the Asian population more precisely,” Yang says.
“Communication is better because we are closer and we speak their language.”